# Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

> **NCT03162250** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Bacteremia

## Interventions

- **DRUG:** DSTA4637S
- **DRUG:** Placebo
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT03162250
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-13
- **Primary completion:** 2020-01-15
- **Final completion:** 2020-01-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03162250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03162250, "Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03162250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*